709 related articles for article (PubMed ID: 20614454)
1. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonist therapy in early Parkinson's disease.
Stowe RL; Ives NJ; Clarke C; van Hilten J; Ferreira J; Hawker RJ; Shah L; Wheatley K; Gray R
Cochrane Database Syst Rev; 2008 Apr; (2):CD006564. PubMed ID: 18425954
[TBL] [Abstract][Full Text] [Related]
3. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
; Gray R; Ives N; Rick C; Patel S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE
Lancet; 2014 Sep; 384(9949):1196-205. PubMed ID: 24928805
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
[TBL] [Abstract][Full Text] [Related]
6. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
[TBL] [Abstract][Full Text] [Related]
7. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease.
Stowe R; Ives N; Clarke CE; Handley K; Furmston A; Deane K; van Hilten JJ; Wheatley K; Gray R
Mov Disord; 2011 Mar; 26(4):587-98. PubMed ID: 21370258
[TBL] [Abstract][Full Text] [Related]
9. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase B inhibitors for early Parkinson's disease.
Macleod AD; Counsell CE; Ives N; Stowe R
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Caslake R; Macleod A; Ives N; Stowe R; Counsell C
Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.
Ives NJ; Stowe RL; Marro J; Counsell C; Macleod A; Clarke CE; Gray R; Wheatley K
BMJ; 2004 Sep; 329(7466):593. PubMed ID: 15310558
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KD
Cochrane Database Syst Rev; 2001; 2001(1):CD001519. PubMed ID: 11279721
[TBL] [Abstract][Full Text] [Related]
14. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.
Kulisevsky J; Pagonabarraga J
Drug Saf; 2010 Feb; 33(2):147-61. PubMed ID: 20082541
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M; Clarke J A
Cochrane Database Syst Rev; 2000; 2000(3):CD002259. PubMed ID: 10908539
[TBL] [Abstract][Full Text] [Related]
16. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001517. PubMed ID: 11279719
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; 2001(3):CD001517. PubMed ID: 10908504
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; 2001(1):CD001518. PubMed ID: 11279720
[TBL] [Abstract][Full Text] [Related]
19. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
Xie CL; Zhang YY; Wang XD; Chen J; Chen YH; Pa JL; Lin SY; Lin HZ; Wang WW
Neurol Sci; 2015 Aug; 36(8):1319-29. PubMed ID: 25981231
[TBL] [Abstract][Full Text] [Related]
20. Off spells and dyskinesias: pharmacologic management of motor complications.
Khan TS
Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
